GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Fuan Pharmaceutical Group Co 300194.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

3.63

-0.82%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.74bn

FY2016FY2025

Net income

CN¥77.0m

FY2016FY2025

Free cash flow

CN¥203.9m

FY2016FY2025

Shareholders' equity

CN¥4.36bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.74bnCN¥2.39bnCN¥2.65bnCN¥2.42bnCN¥2.45bnCN¥2.37bnCN¥2.78bnCN¥2.67bnCN¥2.09bnCN¥1.30bn
Gross profitCN¥642.6mCN¥1.22bnCN¥1.37bnCN¥1.36bnCN¥1.52bnCN¥1.53bnCN¥1.75bnCN¥1.61bnCN¥1.16bnCN¥590.4m
Research and developmentCN¥134.7mCN¥156.8mCN¥135.0mCN¥142.9mCN¥120.4mCN¥86.9mCN¥108.0mCN¥119.8mCN¥96.6mCN¥52.4m
Operating incomeCN¥96.4mCN¥320.8mCN¥298.5mCN¥178.5m−CN¥591.0mCN¥240.8mCN¥326.6m−CN¥321.1mCN¥329.2mCN¥265.6m
Net incomeCN¥77.0mCN¥279.8mCN¥231.9mCN¥204.6m−CN¥296.9mCN¥209.4mCN¥292.8m−CN¥360.0mCN¥284.8mCN¥222.0m
Diluted earnings per share0.060.270.180.19-0.250.210.26-0.300.240.21

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥5.76bnCN¥5.98bnCN¥5.98bnCN¥5.88bnCN¥5.71bnCN¥5.97bnCN¥4.74bnCN¥4.29bnCN¥4.69bnCN¥4.40bn
Cash and short-term investments—CN¥876.3mCN¥996.9mCN¥703.7mCN¥1.00bnCN¥929.1mCN¥861.6mCN¥600.7mCN¥352.6mCN¥276.7m
Total liabilitiesCN¥1.40bnCN¥1.58bnCN¥1.83bnCN¥1.93bnCN¥1.84bnCN¥1.42bnCN¥746.6mCN¥598.6mCN¥518.2mCN¥434.0m
DebtCN¥406.0mCN¥527.4mCN¥837.8mCN¥714.2mCN¥906.0mCN¥601.7mCN¥115.7mCN¥87.0m—CN¥54.0m
Shareholders' equityCN¥4.36bnCN¥4.40bnCN¥4.14bnCN¥3.95bnCN¥3.73bnCN¥4.10bnCN¥3.99bnCN¥3.69bnCN¥4.17bnCN¥3.96bn
Shares outstanding1,300m1,045m1,284m1,104m1,182m987m1,123m1,184m1,188m1,069m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥312.3mCN¥303.6mCN¥329.0mCN¥339.5mCN¥257.1mCN¥162.6mCN¥295.6mCN¥267.7mCN¥453.4mCN¥374.2m
Capital spending−CN¥108.4m−CN¥241.8m−CN¥215.7m−CN¥383.1m−CN¥413.0m−CN¥344.5m−CN¥223.8m−CN¥132.2m−CN¥84.6m−CN¥153.9m
Free cash flowCN¥203.9mCN¥61.8mCN¥113.3m−CN¥43.6m−CN¥155.9m−CN¥182.0mCN¥71.8mCN¥135.5mCN¥368.7mCN¥220.2m
Dividends paid−CN¥105.0m−CN¥84.2m−CN¥94.0m−CN¥28.1m−CN¥59.5m−CN¥59.5m−CN¥2.4m−CN¥120.4m−CN¥80.6m−CN¥40.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥431.8mCN¥407.5mCN¥422.9mCN¥394.9mCN¥452.8mCN¥467.7mCN¥396.2mCN¥562.3m
Gross profitCN¥166.9mCN¥165.4mCN¥160.1mCN¥154.1mCN¥137.8mCN¥190.5mCN¥160.7mCN¥306.3m
Operating incomeCN¥54.8mCN¥42.6mCN¥13.7mCN¥49.3mCN¥46.6mCN¥73.2m−CN¥26.4mCN¥97.3m
Net incomeCN¥40.9mCN¥54.9m−CN¥89.3mCN¥53.1mCN¥44.1mCN¥69.0m−CN¥21.8mCN¥85.1m
Diluted earnings per share0.030.04-0.070.040.030.05-0.020.08
Cash from operations———CN¥100.0mCN¥34.0mCN¥26.0m—CN¥53.0m
Capital spending−CN¥13.0m−CN¥33.0m−CN¥13.0m−CN¥22.0m−CN¥20.0m−CN¥52.0m−CN¥75.0m−CN¥50.0m
Free cash flow———CN¥78.0mCN¥14.0m−CN¥26.0m—CN¥3.0m
Total assetsCN¥5.62bnCN¥5.63bnCN¥5.76bnCN¥5.97bnCN¥5.99bnCN¥6.08bnCN¥5.98bnCN¥6.04bn
Cash and short-term investments———CN¥1.06bnCN¥986.2mCN¥1.01bnCN¥876.3mCN¥969.1m
DebtCN¥250.6mCN¥250.6mCN¥406.0mCN¥565.8mCN¥819.2mCN¥839.3mCN¥526.9mCN¥532.5m
Shareholders' equityCN¥4.40bnCN¥4.42bnCN¥4.36bnCN¥4.45bnCN¥4.44bnCN¥4.45bnCN¥4.40bnCN¥4.40bn

Financial ratios

Data as of 16 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin37.0%50.9%51.6%56.0%61.8%64.6%
Operating margin6.1%14.1%12.1%9.0%-23.2%10.6%
Net margin4.4%11.7%8.8%8.4%-12.1%8.8%
Return on equity1.8%6.4%5.6%5.2%-8.0%5.1%
Return on assets1.3%4.7%3.9%3.5%-5.2%3.5%
Free cash flow yield8.3%13.4%10.9%16.7%14.5%13.1%
Revenue growth-27.3%-9.7%9.3%-1.3%3.6%-14.8%
Earnings growth-72.5%20.7%13.3%-168.9%-241.8%-28.5%
Current ratio2.32x1.68x1.78x1.50x1.62x1.84x
Debt to equity0.09x0.12x0.20x0.18x0.24x0.15x
Equity ratio75.7%73.5%69.4%67.1%65.4%68.6%
Interest coverage4.76x14.09x10.55x7.88x-26.13x23.46x
R&D as a share of sales7.7%6.6%5.1%5.9%4.9%3.7%
Buybacks as a share of market value-24.5%18.6%-16.3%6.6%-19.7%12.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-10.5%-6.0%9.4%
Operating income-18.6%-16.7%2.1%
Net income-27.8%-18.1%1.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin45.0%49.8%54.4%55.3%
Operating margin10.1%9.7%3.9%5.2%
Net margin8.6%8.6%5.0%5.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings74.716.624.319.4-20.423.221.3-10.624.042.2
Price to sales3.31.92.11.62.52.02.21.43.37.2

Dividends and splits

Per share, in the currency the company pays

Paid for 3 years. Last went ex-dividend on 28 May 2026.

FY2026FY2025FY2024FY2023FY2021FY2020FY2018FY2017
Paid in the year0.050.070.050.050.050.050.100.067
  • 3-for-1 split · 10 May 2017
  • 3-for-2 split · 13 May 2014
  • 13-for-10 split · 14 May 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.